Structural and dynamics analysis of matrix metalloproteinases MMP-2 complexed with chemically modified tetracyclines (CMTs)

References

• Acharya, M. R., Venitz, E., Figg, W. D., & Sparreboom, A. (2004). Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resistance Updates, 7, 195–208.
   PubMed Web of Science ®Google Scholar
• Chakrabarti, B., Bairagya, H. R., Mallik, P., Mukhopadhyay, B. P., & Bera, A. K. (2011). An insight to conserved water molecular dynamics of catalytic and structural Zn+2 ions in matrix metalloproteinase 13 of human. Journal of Biomolecular Structure & Dynamics, 28, 503–516.
   PubMed Web of Science ®Google Scholar
• Dezube, B. J., Krown, S. E., Lee, J. Y., Bauer, K. S., & Aboulafia, D. M. (2006). Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: An AIDS malignancy consortium study. Journal of Clinical Oncology, 24, 1389–1394.
   PubMed Web of Science ®Google Scholar
• Dhanaraj, V., Williams, M. G., Ye, Q. Z., Molina, F., Johnson, L. L., Ortwine, D. F., … Blundell, T. L. (1999). X-ray structure of gelatinase a catalytic domain complexed with a hydroxamate inhibitor. Croatica Chemica Acta, 72, 575–591.
   Web of Science ®Google Scholar
• Glaser, F., Rosenberg, Y., Kessel, A., Pupko, T., & Ben-Tal, N. (2005). The ConSurf-HSSP database: The mapping of evolutionary conservation among homologs onto PDB structures. Proteins-structure function and bioinformatics, 58, 610–617.
   PubMed Web of Science ®Google Scholar
• Griffin, M. O., Ceballos, G., & Villarreal, F. J. (2011). Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action. Pharmacological Research, 63, 102–107.
   PubMed Web of Science ®Google Scholar
• Gu, Y., Lee, H. M., Golub, L. M., Sorsa, T., Konttinen, Y. T., & Simon, S. R. (2005). Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Annals of Medicine, 37, 450–460.
   PubMed Web of Science ®Google Scholar
• Gu, Y., Lee, H.-M., Simon, S. R., & Golub, L. M. (2011). Chemically modified tetracycline-3 (CMT-3): A novel inhibitor of the serine proteinase, elastase. Pharmacological Research, 64, 595–601.
   PubMed Web of Science ®Google Scholar
• Holmes, S., Smith, S., Borthwick, L., Dunford, J., Rogers, M., Bishop, N., & Grabowski, P. S. (2008). CMT3 alters mitochondrial function in murine osteoclast lineage cells. Biochemical and Biophysical Research Communications, 365, 840–845.
   PubMed Web of Science ®Google Scholar
• Kozelka, J., Legendre, F., Reeder, F., & Chottard, J. C. (1999). Kinetic aspects of interactions between DNA and platinum complexes. Coordination Chemistry Reviews, 192, 61–82.
   Google Scholar
• Kumar, V., Abbas, A. K., & Aster, J. C. (2013). Basic pathology. Toronto: Elsevier.
   Google Scholar
• Li, N. G., Shi, Z. H., Tang, Y. P., & Duan, J. A. (2009). Selective matrix metalloproteinase inhibitors for cancer. Current Medicinal Chemistry, 16, 3805–3827.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Ramamurthy, N. S., Marecek, J., Lee, H. M., Chen, J. L., Ryan, M. E., … Golub, L. M. (2001). The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). Current Medicinal Chemistry, 8, 243–252.
   PubMedGoogle Scholar
• Marcial, B. L., Sousa, S. F., Barbosa, I. L., Dos Santos, H. F., & Ramos, M. J. (2012). Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: A molecular and structural study. Journal of Physical Chemistry B, 116, 13644–13654.
   PubMed Web of Science ®Google Scholar
• Mayrose, I., Graur, D., Ben-Tal, N., & Pupko, T. (2004). Comparison of site-specific rate-inference methods for protein sequences: Empirical Bayesian methods are superior. Molecular Biology and Evolution, 21, 1781–1791.
   PubMed Web of Science ®Google Scholar
• McQuarrie, D. A. (2000). Statistical Mechanics. Sausalito, CA: University Science Book.
   Google Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30, 2785–2791.
   PubMed Web of Science ®Google Scholar
• Nuti, E., Tuccinardi, T., & Rossello, A. (2007). Matrix metalloproteinase inhibitors: New challenges in the era of post broad-spectrum inhibitors. Current Pharmaceutical Design, 13, 2087–2100.
   PubMedGoogle Scholar
• Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27, 5287–5297.
   PubMed Web of Science ®Google Scholar
• Seftor, R. E. B., Seftor, E. A., De Larco, J. E., Kleiner, D. E., Leferson, J., Stetler-Stevenson, W. G., … Hendrix, M. J. C. (1998). Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clinical & Experimental Metastasis, 16, 217–225.
   PubMed Web of Science ®Google Scholar
• Sousa, S. F., Lopes, A. B., Fernandes, P. A., & Ramos, M. J. (2009). The zinc proteome: A tale of stability and functionality. Dalton Transactions, 7946–7956.
   PubMed Web of Science ®Google Scholar
• Sousa, S. F., Fernandes, P. A., & Ramos, M. J. (2008a). Enzyme flexibility and the catalytic mechanism of farnesyltransferase: Targeting the relation. Journal of Physical Chemistry B, 112, 8681–8691.
   PubMed Web of Science ®Google Scholar
• Sousa, S. F., Fernandes, P. A., & Ramos, M. J. (2008b). Molecular dynamics analysis of farnesyltransferase: A closer look into the amino acid behavior. International Journal of Quantum Chemistry, 108, 1939–1950.
   Web of Science ®Google Scholar
• Sousa, S. F., Fernandes, P. A., & Ramos, M. J. (2009). Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme. Bioorganic & Medicinal Chemistry, 17, 3369–3378.
   PubMed Web of Science ®Google Scholar
• Syed, S., Takimoto, C., Hidalgo, M., Rizzo, J., Kuhn, J. G., Hammond, L. A., … Rowinsky, E. K. (2004). A phase I and pharmacokinetic study of Col-3 (metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clinical Cancer Research, 10, 6512–6521.
   PubMed Web of Science ®Google Scholar
• Tamames, B., Sousa, S. F., Tamames, J., Fernandes, P. A., & Ramos, M. J. (2007). Analysis of zinc-ligand bond lengths in metalloproteins: Trends and patterns. Proteins-Structure Function and Bioinformatics, 69, 466–475.
   PubMed Web of Science ®Google Scholar
• Terp, G. E., Christensen, I. T., & Jorgensen, F. S. (2000). Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes. Journal of Biomolecular Structure & Dynamics, 17, 933–946.
   PubMed Web of Science ®Google Scholar
• Valente, M., Sousa, S. F., Magalhaes, A. L., & Freire, C. (2012). Dehydration of a polyether type extraction agent and of the corresponding K+ complex: Insights into liquid-liquid extraction mechanisms by quantum chemical methods. Journal of Molecular Modeling, 18, 4909–4915.
   PubMed Web of Science ®Google Scholar
• Vallee, B. L., & Auld, D. S. (1990). Active-site zinc ligands and activated H2O of zinc enzymes. Proceedings of the National Academy of Sciences of the United States of America, 87, 220–224.
   PubMed Web of Science ®Google Scholar
• Zitka, O., Kukacka, J., Krizkova, S., Huska, D., Adam, V., Masarik, M., … Kizek, R. (2010). Matrix metalloproteinases. Current Medicinal Chemistry, 17, 3751–3768.
   PubMed Web of Science ®Google Scholar